Nanobiotix Euronext Paris trading halt
Analysis based on 7 articles · First reported May 21, 2026 · Last updated May 21, 2026
The temporary trading halt of Nanobiotix shares on Euronext Paris directly impacts the liquidity and immediate valuation of Nanobiotix. While the halt is for administrative purposes related to a Global Offering, it can create short-term uncertainty for investors until trading resumes and pricing is announced.
Nanobiotix, a late-clinical stage biotechnology company, announced a temporary trading halt of its ordinary shares on Euronext Paris starting May 21, 2026, at 9:00 a.m. CEST. This halt was requested by Nanobiotix to facilitate the confirmation of investor allocations and the announcement of the pricing for its previously disclosed Global Offering. The Global Offering includes a U.S. public offering of American Depositary Shares and an International Offering of ordinary shares and pre-funded warrants to qualified investors in Europe and other selected countries, excluding the United States and Canada. Trading on Euronext Paris is expected to resume later the same day at approximately 3:30 p.m. Paris time.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard